The Spartan RX is the first sample-to-result point-of-care DNA testing system. The CYP2C19 test kit identifies carriers of the CYP2C19*2 allele.

  • 30% of the population carries the *2 allele.1 This results in decreased activation of drugs such as Plavix® (clopidogrel).

  • *2 carriers have a 42% higher risk of death, stroke, or second heart attack after cardiac stenting and starting Plavix®.2

  • For *2 carriers, 40%–50% of Major Adverse Cardiac Events (MACE) occur within the first 24–48 hours.2,3

  • In March 2010, the FDA issued a 'black box' warning for Plavix® regarding the CYP2C19 genetic issue.


The Spartan RX CYP2C19 system is fast, affordable, and reliable:

  • Four easy steps can be performed by nurses and non-technical staff:
  1. Swab cheek
  2. Add sample to cartridge
  3. Place sample into Spartan RX
  4. Press "Begin Test"
  • Results print automatically in 1 hour
  • Results are 100% concordant with central lab methods
  • CE IVD Mark regulatory approval

NOTE: This product is not available for sale in the United States.


1 Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
2 Mega JL et al. (2009). N Engl J Med. 360:354–62.
3 Wiviott SD et al. (2007). N Engl J Med. 357:2001–2015.